Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

GlobeNewswire November 5, 2024

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

GlobeNewswire October 31, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

GlobeNewswire October 23, 2024

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

GlobeNewswire October 17, 2024

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

GlobeNewswire September 11, 2024

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

GlobeNewswire September 5, 2024

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

GlobeNewswire August 6, 2024

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

GlobeNewswire August 1, 2024

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

GlobeNewswire August 1, 2024

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

GlobeNewswire July 18, 2024

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

GlobeNewswire June 15, 2024

Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET

GlobeNewswire June 6, 2024

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

GlobeNewswire June 3, 2024

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

GlobeNewswire May 30, 2024

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

GlobeNewswire May 28, 2024

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

GlobeNewswire May 14, 2024

Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024

GlobeNewswire May 6, 2024

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

GlobeNewswire May 3, 2024

Agios Reports Business Highlights and First Quarter 2024 Financial Results

GlobeNewswire May 2, 2024

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

GlobeNewswire April 18, 2024